On the risk of delisting of ordinary shares of Moleculin Biotech, Inc. (MBRX)

The International Trading System Limited (hereinafter – ITS) hereby informs on the delisting risk of ordinary shares of Moleculin Biotech, Inc. (ISIN US60855D3098, hereinafter – Shares, QI) from The NASDAQ Stock Market LLC (hereinafter - Nasdaq).  

Information on delisting risk of ordinary shares by Nasdaq

On May 23, 2025 Moleculin Biotech, Inc. (hereinafter – the Company) submitted Current report Form 8-K to The United States Securities and Exchange Commission (hereinafter – SEC). According to the report, on May 23, 2025, the Company received a written notice from Nasdaq notifying the Company that it was not in compliance with the minimum stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b)(1), because the Company’s stockholders’ equity was below the required minimum of $2.5 million.

The Company has 45 days from receipt of the Notice to submit to Nasdaq a plan to regain compliance with the Stockholders’ Equity Requirement. If Nasdaq accepts the Company’s plan, Nasdaq may grant an extension of up to 180 calendar days from the date of the Notice for the Company to evidence compliance. For more information, please refer to the report available on the SEC website.

Information regarding possible actions to be taken by ITS Ltd.

If Nasdaq suspends trading in the Company’s ordinary shares, ITS will prohibit submission of orders and will restrict ability to conclude agreements in respect of the Company’s ordinary shares. If the Company’s ordinary shares are delisted from Nasdaq, ITS will terminate trading in the Company’s ordinary shares. However, in case the Company’s ordinary shares become listed, or admitted to trading on another Recognized Trading Venue, ITS will consider but does not guarantee continuation of trading in the Company’s ordinary shares.